Tumor necrosis factor alpha (TNF-α)–Tumor necrosis factor receptor (TNFR) interaction interface (TNF-α–TNFR interface)

The Tumor necrosis factor alpha (TNF-α)–Tumor necrosis factor receptor (TNFR1/TNFR2) interaction interface is a pivotal structural domain responsible for mediating pro-inflammatory and apoptotic signaling (UniProt P01375, P19438). TNF-α, a potent cytokine primarily produced by macrophages, functions as a homotrimer that binds to the extracellular cysteine-rich domains of its two cognate receptors, TNFR1 and TNFR2 (PubMed: 21179053). This binding event triggers intracellular pathways, including the NF-κB and MAPK cascades, which regulate immune responses, cell survival, and programmed cell death (StatPearls: TNF Inhibitors). Dysregulation of this interface is a hallmark of numerous autoimmune and inflammatory pathologies, such as rheumatoid arthritis and inflammatory bowel disease (NIH: MedlinePlus). Therapeutic intervention typically involves the use of monoclonal antibodies or decoy receptors that sterically hinder the interaction at this interface (PubChem: Adalimumab). These biologics effectively sequester soluble and membrane-bound TNF-α, preventing the formation of the signaling complex. Recent drug discovery efforts are also exploring small-molecule inhibitors that stabilize inactive conformations of the TNF-α trimer, effectively disrupting the interface and preventing receptor assembly (Nature Communications: 10.1038/s41467-019-13616-1). This target remains a cornerstone of modern rheumatology and gastroenterology.

Other names

TNF-TNFR1/2 interfaceTNF-TNFR complexTumor necrosis factor-receptor binding siteTNF-TNFR interaction site

Blockade of the physical interaction between the TNF-α homotrimer and its receptors (TNFR1 and TNFR2) to inhibit pro-inflammatory signaling cascades (StatPearls: TNF Inhibitors).